Azacitidine (5-Azacytidine)

Name: Azacitidine (5-Azacytidine)
Brand: Selleck Chemicals
SKU: S1782
Rating: 5 (58 reviews)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza, CC-486

58 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza, CC-486) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Selleck's Azacitidine (5-Azacytidine) has been cited by 58 publications

Cancer Cell, 2019, 35(2):333-335

PubMed: 30753831 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):724-740.e4

PubMed: 30423294 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31382-X

PubMed: 29249359 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

J Hematol Oncol, 2021, 14(1):70

PubMed: 33902674 ( click the link to review the publication )

JCI Insight, 2021, 6(17)146196

PubMed: 34375307 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):570

PubMed: 34108444 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):90

PubMed: 33941774 ( click the link to review the publication )

Sci Rep, 2021, 11(1):6270

PubMed: 33737539 ( click the link to review the publication )

Sci Rep, 2021, 11(1):5715

PubMed: 33707624 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Blood Adv, 2021, 5(10):2467-2480

PubMed: 33999145 ( click the link to review the publication )

Transgenic Res, 2021, 30(1):63-76

PubMed: 33394315 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Front Immunol, 2020, 11:594540

PubMed: 33569051 ( click the link to review the publication )

Neoplasia, 2020, 22(3):142-153

PubMed: 32062068 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Technol Cancer Res Treat, 2020,

PubMed: 32715976 ( click the link to review the publication )
Target Oncol, 2020, 15(2):231-240

PubMed: 32222953 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4393-4405

PubMed: 32926125 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Clin Transl Oncol, 2020, 10.1007/s12094-020-02464-x

PubMed: 32737836 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

J Biochem Mol Toxicol, 2020, e22621

PubMed: 32894642 ( click the link to review the publication )

Stem Cell Reports, 2020, 15(2):408-423

PubMed: 32735821 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128571

PubMed: 31437130 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Environ Toxicol, 2019, 10.1002/tox.22873

PubMed: 31724259 ( click the link to review the publication )

J Pharmacol Sci, 2019, 140(2):187-192

PubMed: 31345653 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

Med Sci Monit, 2019, 25:9426-9434

PubMed: 31822650 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30412053 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 5;37(1):305

PubMed: 30518424 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )
Int J Mol Sci, 2018, 19(5)E1414

PubMed: 29747401 ( click the link to review the publication )

Int J Mol Sci, 2018, 20(1)

PubMed: 30577584 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(9):1243-1254

PubMed: 28522693 ( click the link to review the publication )

Leuk Res, 2017, 58:91-97

PubMed: 28505595 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

FEBS J, 2016, 283(20):3739-3754

PubMed: 27573079 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Sci Transl Med, 2015, 7(290):290ra89

PubMed: 26041706 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methyltransferase ^[1]
(Cell-free assay)

In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. ^[1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. ^[2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Raji	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vWXlAvOS13MDFOwG0>	MnrNNVIuPzJiaB?=		MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NXfzSGpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|MzPDZpPkK2NVM{OjR4PD;hQi=>
Jurkat	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSwMlEuPTBizszN	NEDYWncyOi15MjDo		Mof0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M4LBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUOzNlQ3Lz5{NkGzN\|I1PjxxYU6=
CA46	MmGxSpVv[3Srb36gRZN{[Xl?	NUTZWnExOjEEoNM1US=>	NY\MXpFYPDhiaB?=		MmfYbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w	MnjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{OyOFYoRjJ4MUOzNlQ3RC:jPh?=
Raji	NH;LOYZHfW6ldHnvckBCe3OjeR?=	MUixOeKhyrWP	MXe0PEBp		MYfpcoNz\WG\|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25?	MoDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{OyOFYoRjJ4MUOzNlQ3RC:jPh?=
Jurkat	NIX3OpdHfW6ldHnvckBCe3OjeR?=	NEe5PJg{NjYEoNM1US=>	NFHuVJg1QCCq		Mnq4bY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w	M{izNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUOzNlQ3Lz5{NkGzN\|I1PjxxYU6=
MDA-MB-231	MlvLSpVv[3Srb36gRZN{[Xl?	NFjMPVQyNzJwNT:1JO69VQ>?	NIizemU1QCCq		MXXk[YNz\WG\|ZYOgeIhmKFCWUF6xNkBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kA2yqEQvF2gOFjDqGh?	Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUeyNlkoRjJ3OEG3NlI6RC:jPh?=
MDA-MB-231	M1jmcmZ2dmO2aX;uJGF{e2G7	M1L2cFEwOi53L{Wg{txO	NIjleI01QCCq		MX7pcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCHLXPh[IhmemmwIH3SUmEh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFIvPcLizszN[o9zKDR6wrDo	NHHlOGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixO\|IzQSd-MkW4NVczOjl:L3G+
MDA-MB-231	MoXBSpVv[3Srb36gRZN{[Xl?	MVGxM\|IvPS93IN88US=>	NGW3XJIzPC92ODDo		MnrEbY5lfWOnczCgd4lodmmoaXPhcpQhWEGUUDDjcIVifmGpZTDh[pRmeiB2ODDo	NWTpZXNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVczOjlpPkK1PFE4OjJ7PD;hQi=>
MCF-7	MVXGeY5kfGmxbjDBd5NigQ>?	M{jsNFEwOi53L{Wg{txO	MVeyOE81QCCq		MY\pcoNz\WG\|ZYOgVGFTWCClbHXheoFo\cLi	M3m5O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEG3NlI6Lz5{NUixO\|IzQTxxYU6=
MDA-MB-231	MmTYSpVv[3Srb36gRZN{[Xl?	MYOxM\|IvPS93IN88US=>	NXWzb49HOjRxNEigbC=>		MkTmbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJI1qWk6DLUGyOEBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gOUDPxE1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzN{KyPUc,OjV6MUeyNlk9N2F-
A498	Ml:ySpVv[3Srb36gRZN{[Xl?	MnzMNVAhyrWP	MYG3NkBp		NHTOOoVqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44>	M2D4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[5NFg3Lz5{NUW2PVA5PjxxYU6=
CaKI-2	MV7GeY5kfGmxbjDBd5NigQ>?	NFWwZmIyOCEEtV2=	MlTkO\|IhcA>?		M2LMNYlv\HWlZYOgeIhmKEGGQV3UV\|E5KGenbnWg[ZhxemW\|c3nvci=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4OUC4Okc,OjV3NkmwPFY9N2F-
Ketr-3	NWTmTnlITnWwY4Tpc44hSXO\|YYm=	NIDaVJAyOCEEtV2=	MnTlO\|IhcA>?		M{LJO4lv\HWlZYOgeIhmKEGGQV3UV\|E5KGenbnWg[ZhxemW\|c3nvci=>	M4S2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[5NFg3Lz5{NUW2PVA5PjxxYU6=
A253	NF\MeoxHfW6ldHnvckBCe3OjeR?=	MYexNEDDvU1?	MVSwMVQh\A>?		NGTRR\|ZqdmO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCuZY\lcEBw\iC2aHWgUVNTyqCjZoTldkAzPCCq	MonXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEW1N\|YoRjJ3NEi1OVM3RC:jPh?=
A253	NFj2eGlHfW6ldHnvckBCe3OjeR?=	NXvEeHd6OTBiwsXN	MkX1O\|IhcA>?		MV7pcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6NUWzOkc,OjV2OEW1N\|Y9N2F-
A253	MYTGeY5kfGmxbjDBd5NigQ>?	MlWxNVAhyrWP	NGC4UGQxNTRiZB?=		NIq5[2lz\WS3Y3XzJJRp\SB3LX3leIh6dGO7dH;zbY5mKGOxboTlcpQ>	MnfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEW1N\|YoRjJ3NEi1OVM3RC:jPh?=
PC3	NY\2ZYpwTnWwY4Tpc44hSXO\|YYm=	M4mye\|AvOiEQvF5CpC=>	NFHpSGc1KGR?		MXvpcoNz\WG\|ZYOgeIhmKGenbnWg[ZhxemW\|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4	NF3mfW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|M1OCd-MkW0O\|c{PDB:L3G+
MCF7	MkHWSpVv[3Srb36gRZN{[Xl?	M4TVNFAvOyEQvF5CpC=>	MVy0JIQ>		MUnpcoNz\WG\|ZYOgeIhmKGenbnWg[ZhxemW\|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4	NUf1dVY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{PDBpPkK1OFc4OzRyPD;hQi=>
PC3	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXqwMlIh\|ryPwrC=	NEDsZ3A1KGR?		MYLk[YNz\WG\|ZYOgeIhmKGOnbHyg[5Jwf3SqIITvJFIxNjNnIHPvcYJqdmWmIIfpeIghT1ONMUK2	M3[xb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|QxLz5{NUS3O\|M1ODxxYU6=
MCF7	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPod41yOC5\|IN88UeKh	M3;YZlQh\A>?		NVKwXmtE\GWlcnXhd4V{KHSqZTDj[YxtKGe{b4f0bEAzPC56JTDjc41jcW6nZDD3bZRpKEeVS{GyOi=>	NGHOOXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|M1OCd-MkW0O\|c{PDB:L3G+
BGC-823	M1LaTmZ2dmO2aX;uJGF{e2G7	NEe1WpE2yqEQvF2=	NUG3U5NJPzJiaB?=		NXvwdpJL\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5NUezN{c,OjV2N{W3N\|M9N2F-
MKN28	MXLGeY5kfGmxbjDBd5NigQ>?	M{PFW\|XDqM7:TR?=	MUG3NkBp		M33SR4Rm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk>	MoPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N\|MoRjJ3NEe1O\|M{RC:jPh?=
SGC-7901	MV;GeY5kfGmxbjDBd5NigQ>?	M2fvPFXDqM7:TR?=	Mkn2O\|IhcA>?		NID5bZBl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6	NW\xO2VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|U4OzNpPkK1OFc2PzN\|PD;hQi=>
MKN45	MYLGeY5kfGmxbjDBd5NigQ>?	MlrXOeKh\|ryP	Mn\vO\|IhcA>?		NW\CZYlT\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>?	MnrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N\|MoRjJ3NEe1O\|M{RC:jPh?=
BGC-823	NILMRVZHfW6ldHnvckBCe3OjeR?=	M3LQ[\|XDqM7:TR?=	MU[3NkBp		MmLN[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?=	M2HFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe1O\|M{Lz5{NUS3OVc{OzxxYU6=
MKN28	NVTPd4pCTnWwY4Tpc44hSXO\|YYm=	MX[1xsDPxE1?	NEnNdW04OiCq		Ml25[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?=	MonpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N\|MoRjJ3NEe1O\|M{RC:jPh?=
SGC-7901	NYLrfVJpTnWwY4Tpc44hSXO\|YYm=	M1nqW\|XDqM7:TR?=	MVu3NkBp		MlTi[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?=	NFn2O5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3OVc{Oyd-MkW0O\|U4OzN:L3G+
MKN45	MmTBSpVv[3Srb36gRZN{[Xl?	MVy1xsDPxE1?	M2rtcFczKGh?		M2rqVIRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm=	NYjacFlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|U4OzNpPkK1OFc2PzN\|PD;hQi=>
HREC	NI\SXGlHfW6ldHnvckBCe3OjeR?=	MnTPOU8yOMLizszN	MVW0PEBp		M2r2eYlv\HWlZYOgVGVFTiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV\|NUK3OFc9N2F-
HRPE	MX3GeY5kfGmxbjDBd5NigQ>?	NGjISm02NzFywrFOwG0>	NXfVcnp7PDhiaB?=		NIHP[mFqdmS3Y3XzJHBGTEZiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV\|NUK3OFc9N2F-
HREC	NWL1boxoTnWwY4Tpc44hSXO\|YYm=	NF7QSXE2NzFywrFOwG0>	M3fzeFQ5KGh?		MYrkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLQ1HNMVEhMG6xdDDwdo91\WmwIHzleoVtKGmwIFjSVGUh[2WubIOpMEBKVC1zzsKg[I9{\S2mZYDlcoRmdnSueR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV\|NUK3OFc9N2F-
HRPE	NIfVcZlHfW6ldHnvckBCe3OjeR?=	M2XINFUwOTEEoN88US=>	M{T3XFQ5KGh?		NXnGXGVb\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWwuOc7{LDDhcoQhVU2SMjDkc5NmNWSncHXu[IVvfGy7	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV\|NUK3OFc9N2F-
MSCs	MYrGeY5kfGmxbjDBd5NigQ>?	MYWxNEDPxE1?	M4rnNlI1KGh?		MmTndJJwdW:2ZYOgeIhmKGOxbX3peI1mdnRib3[gUXNEeyC2bzDtfY9k[XKmaXHsJIRq\m[ncnXueIlifGmxbh?=	NXPMfZBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOVE{QTVpPkK1N\|UyOzl3PD;hQi=>
HL-60	MlzaSpVv[3Srb36gRZN{[Xl?	MUC1JO69VQ>?	MlzwO\|IhcA>?	MlfLSG1UVw>?	NVLjbXl4e2mpbnnmbYNidnSueTD1dJJm\3WuYYTld{BbVkZ\|OEKg[ZhxemW\|c3nvci=>	MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MUmwOFkoRjJ3M{G5NFQ6RC:jPh?=
MV4-11	M4PqbWZ2dmO2aX;uJGF{e2G7	NILFTpk2KM7:TR?=	NH62[pI4OiCq	NYjmWGZjTE2VTx?=	MnK4d4lodmmoaXPhcpRtgSC3cILl[5Vt[XSnczDaUmY{QDJiZYjwdoV{e2mxbh?=	M4rQR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{G5NFQ6Lz5{NUOxPVA1QTxxYU6=
A2780	NX3hNW1zTnWwY4Tpc44hSXO\|YYm=	MnTyOUDDvU4EoB?=	MmHpO{Bl		NV7kWZpscW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?=	MlnmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
CP70	M{LrbWZ2dmO2aX;uJGF{e2G7	M2\iOVUhyrWPwrC=	NIDCbpk4KGR?		NFHvOo1qdmO{ZXHz[ZMhTE6DIH3leIh6dGG2aX;uJIxmfmWu	MljwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
A2780	M3r3SWZ2dmO2aX;uJGF{e2G7	NX3K[IZMPSEEtV5CpC=>	NUK1[YNVPyCm		NVf6epdnf2Wja3Xud{B1cGVibHX2[Ywhd2ZibXX0bJlt[XSrb36=	NUPwT3czRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVk3QTRpPkK1Nlk6Pjl2PD;hQi=>
CP70	Moq1SpVv[3Srb36gRZN{[Xl?	MWq1JOK2VcLi	MXW3JIQ>		MnfNe4Vic2WwczD0bIUhdGW4ZXygc4YhdWW2aInsZZRqd25?	MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
OCM3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6wMlUwOS9{IN88US=>	M3fBZ\|ch\A>?	MUPEUXNQ	NXrHZ4VucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M{fwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
92.1	M2jYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrkcZkxNjVxMT:yJO69VQ>?	MVu3JIQ>	MYfEUXNQ	M1jJVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MorFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM1	M3XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jKblAvPS9zL{Kg{txO	MnG2O{Bl	MYrEUXNQ	NUjPOIZGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
OMM1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjTe2gxNjVxMT:yJO69VQ>?	Mm[5O{Bl	MoLISG1UVw>?	M3u4OIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	M1u4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
Mel 285	M4ficGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHP6ZYwxNjVxMT:yJO69VQ>?	NG\CNIQ4KGR?	NVHhe21mTE2VTx?=	MkCybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
Mel 290	NY\scoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjSNE42NzFxMjFOwG0>	NIH4blQ4KGR?	MVHEUXNQ	Mlr4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M{LNPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM3	MUHGeY5kfGmxbjDBd5NigQ>?	NGLxUYsxNjVxMTFOwG0>	NX;DbJp1PDhiaB?=	Mlf2SG1UVw>?	MX;k[YNz\WG\|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6	NEHtbJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
92.1	M37G[mZ2dmO2aX;uJGF{e2G7	NVO2bo9EOC53L{Gg{txO	NYDSTow6PDhiaB?=	M2Lmb2ROW09?	M2LPcoRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM1	NIL2RpZHfW6ldHnvckBCe3OjeR?=	NWSzSWZXOC53L{Gg{txO	MkTxOFghcA>?	M{fQd2ROW09?	NVnlNYpL\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
OMM1	MXHGeY5kfGmxbjDBd5NigQ>?	Mo[2NE42NzFizszN	MlPSOFghcA>?	MXvEUXNQ	M4KweIRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	M1LWbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
Mel 285	M{\qVGZ2dmO2aX;uJGF{e2G7	NF[zeJQxNjVxMTFOwG0>	MofpOFghcA>?	NUjBdXc{TE2VTx?=	MkfU[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	NH7Re5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
Mel 290	NVSyUoJTTnWwY4Tpc44hSXO\|YYm=	MorFNE42NzFizszN	NHHPfnY1QCCq	NYLPd29vTE2VTx?=	M3HYO4Rm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	NYnPZXJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
OCM3	NUjRW4h6TnWwY4Tpc44hSXO\|YYm=	Mm\2NE42NzFizszN	MVG0PEBp	M37UNWROW09?	M1PLfYRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA>	NWLJ[Xl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
Mel 290	NEDSOJFHfW6ldHnvckBCe3OjeR?=	M2DKZVAvPS9zIN88US=>	MV:0PEBp	M4DE[2ROW09?	NHnacXRl\WO{ZXHz[ZMhcW64YYPpc44h\G:\|ZTDk[ZBmdmSnboTsfeKh	NIK1XGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
OMM1	M2W1PWZ2dmO2aX;uJGF{e2G7	NEPFW4gxNjVxMTFOwG0>	MX[0PEBp	NUfD[5NQTE2VTx?=	MVjk[YNz\WG\|ZYOgbY53[XOrb36g[I9{\SCmZYDlcoRmdnSuedMg	M1OxWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM1	NXK5T2E1S2WubDDWbYFjcWyrdImgRZN{[Xl?	MmXaNE42NzFizszN	MV21JIQ>	MV7EUXNQ	NYTnUIkx\GWlcnXhd4V{KHKjZHnheIlwdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIlvcGmkaYTpc44>	NW[3OY5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
92.1	NY\m[2FrS2WubDDWbYFjcWyrdImgRZN{[Xl?	MnjyNE42NzFizszN	M3\NcVUh\A>?	NF7CZnZFVVOR	NGDVc5pl\WO{ZXHz[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgbY5pcWKrdHnvci=>	MlPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM1	Mk\LSpVv[3Srb36gRZN{[Xl?	MXiwMlUwOSEQvF2=	M3f1d\|Q5KGh?	M{LnVGROW09?	NV75R2Y6[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=>	MlT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM3	M1HjcWZ2dmO2aX;uJGF{e2G7	NW\xXnRtOC53L{Gg{txO	NILze3M1QCCq	NVPLZ\|NoTE2VTx?=	NF;YNGlk[XW\|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp	M4LTR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
92.1	MUXGeY5kfGmxbjDBd5NigQ>?	Mnn4NE42NzFizszN	NEnubmQ1QCCq	NGradXNFVVOR	NXHz[2xs[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
IMR32	MlL6SpVv[3Srb36gRZN{[Xl?	MWGzJO69VQ>?	M3rqTFczKGh?	Ml;ZSG1UVw>?	NHnXOoFqdmS3Y3XzxsBxOTlvSV7LOITDqGW6cILld5Nqd28EoIPp[45q\mmlYX70cJk>	NYSyW5UzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFQ5PTBpPkK1NVA1QDVyPD;hQi=>
IMR5-75	NHuy[XRHfW6ldHnvckBCe3OjeR?=	MmmxN{DPxE1?	M12zUlczKGh?	M{DUNmROW09?	NGrZTZhqdmS3Y3XzxsBxOTlvSV7LOITDqGW6cILld5Nqd28EoIPp[45q\mmlYX70cJk>	NWnROpl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFQ5PTBpPkK1NVA1QDVyPD;hQi=>
Be(2)-C	Mn\SSpVv[3Srb36gRZN{[Xl?	MluyN{DPxE1?	M1njb\|czKGh?	NVzvW4VtTE2VTx?=	M3qzOIlv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNEi1NEc,OjVzMES4OVA9N2F-
Bxpc-3	NVXsb5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW5OU8yOCEQvF2=	MYiyOE81QC95MjDo		NGTKVpJqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCEeIDjMVMh[2WubIOgbY4hfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6ncoO=	MkDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N\|EoRjJ3ME[xO\|MyRC:jPh?=
Bxpc-3	NF3X[\|VCeG:ydH;zbZMhSXO\|YYm=	NGfKboU2NzFyIN88US=>	NW\SSFF2OjRxNEivO\|IhcA>?		NETmRXVqdmS3Y3XzJIFxd3C2b4Ppd{BqdiC2aX3lMUBidmRiY3;uZ4VzdnS{YYTpc44hdWGwbnXydy=>	NGD0Xog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVc{OSd-MkWwOlE4OzF:L3G+
Bxpc-3	MofjSpVv[3Srb36gRZN{[Xl?	NF[4SXM2NzFyIN88US=>	M2rMdlI1NzR6L{eyJIg>		MVHk[YNz\WG\|ZYOg{tIu[2G2ZX7pckBmgHC{ZYPzbY9vKGGodHXyJFI1KGh?	Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N\|EoRjJ3ME[xO\|MyRC:jPh?=
Bxpc-3	NETEfXlHfW6ldHnvckBCe3OjeR?=	MnT2OU8yOCEQvF2=	MnznNlQwPDhxN{KgbC=>		MX\k[YNz\WG\|ZYOgZ5lkdGmwREGg[ZhxemW\|c3nvckBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gNVAh\|ryP	MmGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N\|EoRjJ3ME[xO\|MyRC:jPh?=
Bxpc-3	MXXGeY5kfGmxbjDBd5NigQ>?	NGraXno2NzFyIN88US=>	NH7kT48zPC92OD:3NkBp		M1u2eIRwf25vcnXneYxifGWVIHOtcZlkKG2UTlGg[ZhxemW\|c3nvckBqdiC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXydy=>	NV7hb4tRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlE4OzFpPkK1NFYyPzNzPD;hQi=>
HL-60	Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOxMlAh\|ryP	NGXEOmE1QCCq		MYfzbYdvcW[rY3HueIx6KGmwaHnibZR{KEiOLU[wJINmdGxiZ4Lve5RpyqB?	MkTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUGxNVkoRjJ3MEWxNVE6RC:jPh?=
HL-60	NV\FflR6TnWwY4Tpc44hSXO\|YYm=	M2jhPFEvOCEQvF2=	NX3IbYhoPDhiaB?=		NEnBSIxqdmO{ZXHz[ZMheDJzV1HGNU9EUVBzwrDhcoQh[2G\|cHHz[U0{KGW6cILld5Nqd28EoB?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MUGxPUc,OjVyNUGxNVk9N2F-
HL-60	M2TlO2Z2dmO2aX;uJGF{e2G7	NHHTSlMyNjBizszN	NVvmfWFwPDhiaB?=		NGDkeJll\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUGxNVkoRjJ3MEWxNVE6RC:jPh?=
HuTu-80	M1TDT2Z2dmO2aX;uJGF{e2G7	NHPWbZcyNzVxMUCg{txO	NUnlOplVPDhxN{KgbC=>		MX\pcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gbJVu[W5iTmDDNWwyKG2UTlGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MkX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MESwOlIoRjJ2OUC0NFYzRC:jPh?=
Caco2	MkDvSpVv[3Srb36gRZN{[Xl?	NULYfZZiOTBizszN	NESxWJc1QCCq		M2HWRYlv[3KnYYPld{BPWENzTEGg[ZhxemW\|c3nvci=>	MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MESwOlIoRjJ2OUC0NFYzRC:jPh?=
HepG2	MorzSpVv[3Srb36gRZN{[Xl?	NIP4SmQxNTJ3IN88US=>	NFG2bpczPCCq		NHSxNlNl\WO{ZXHz[ZMhe3WkdHnsbZNqdi:tZYjpckB1gXCnIEmgLHBEW0t7KTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6	NGHtV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HepG2	MVLGeY5kfGmxbjDBd5NigQ>?	NYXGeIJFOC1{NTFOwG0>	MmDZNlQhcA>?		NU\tclJscW6lcnXhd4V{KGyxdzDk[Y5{cXS7IHzpdI9xem:2ZXnuJJJm[2WydH;yJEhNTEyUKTDn[Y5mKGW6cILld5Nqd28EoB?=	NHrZXJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HepG2	M3nmbGZ2dmO2aX;uJGF{e2G7	NXPpZpE6OTBizsztxsA>	NF:1ZpgxNTJ2IHi=		M37FdIRm[3KnYYPld:KhWEOVS{pCpIFv\MLiSF3HR3LDqGW6cILld5Nqd25iYX7kJIlv[3KnYYPld{BNTEyUIHX4dJJme3Orb36gZYZ1\XJiNjDo	MlnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUW2OFYoRjJ2OEW1OlQ3RC:jPh?=
HepG2	MXHGeY5kfGmxbjDBd5NigQ>?	MlToNVAh\|ryv	MUmyOEBp		M2DMW5Bzd22xdHXzJIN6fG:\|b3zpZ{Bv\XW2cnHsJIxqeGmmIHHjZ5VufWyjdHnvckBqdmSncHXu[IVvfGy7IH;mJIV5d2enbn;1d{BtcXCxcILveIVqdnN?	M3nYblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW1OlQ3Lz5{NEi1OVY1PjxxYU6=
HepG2	NGrG[29HfW6ldHnvckBCe3OjeR?=	MmfxNVAh\|ryv	NHzBTnMzPCCq		MnnQdJJmfmWwdIOgV3JGSlBicILvZ4V{e2mwZx?=	NIDle3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HC45	Ml7hSpVv[3Srb36gRZN{[Xl?	M4\RcVXDvU4EoB?=	MYS0JIQ>		MkHBdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF?	NEP0epU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2NlgxQSd-MkS3OlI5ODl:L3G+
CNDT2	Mmf4SpVv[3Srb36gRZN{[Xl?	MWq1xtVOyqB?	MX:0JIQ>		Ml\pdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF?	NWPs[GlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlI5ODlpPkK0O\|YzQDB7PD;hQi=>
CNDT2	M2TUSWZ2dmO2aX;uJGF{e2G7	NGTKR2s2yrWPwrC=	MUS0JIQ>		Mn3FbY5kemWjc3XzJIdmdmViZYjwdoV{e2mxbjDv[uKhX0mIMTygVFE3NCCFRFixMOKhVEGPQUGsxsBidmUEoFPUUm5DOQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MkiwPUc,OjR5NkK4NFk9N2F-
T-cells	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DDbVUwOjBizszN	MVqwMVQ5KGh?		NV;zR444cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NWHEflF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O\|U4Ojh\|PD;hQi=>
CD3+ T-cells	MV\GeY5kfGmxbjDBd5NigQ>?	MVy1M\|IxKM7:TR?=	NHPOOm41QCCq		NHLVWYt2eHKnZ4XsZZRmeyCyMUWg[ZhxemW\|c3nvci=>	NGLUd\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells	MknlSpVv[3Srb36gRZN{[Xl?	NIn6d\|Q2NzJyIN88US=>	MmjNOFghcA>?		NGH1eWV2eHKnZ4XsZZRmeyCyMUWg[ZhxemW\|c3nvci=>	M4DFPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
CD8+ T-cells	MmfrSpVv[3Srb36gRZN{[Xl?	NUX1bms{PS9{MDFOwG0>	M2jKRlQ5KGh?		MWr1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?=	NF6xSFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD3+ T-cells	M{jmVGZ2dmO2aX;uJGF{e2G7	NUnOT2ZGPS9{MDFOwG0>	MlvEOFghcA>?		NFHLNnZ2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCIT2jQNy=>	NUHjXY02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O\|U4Ojh\|PD;hQi=>
CD4+ T-cells	MV;GeY5kfGmxbjDBd5NigQ>?	NVjPRpI6PS9{MDFOwG0>	M4fuUVQ5KGh?		NGnZXY12eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCIT2jQNy=>	NH7tXG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells	NYnwRmpRTnWwY4Tpc44hSXO\|YYm=	Mn;4OU8zOCEQvF2=	NFjnPHg1QCCq		MnnUdoVlfWOnczDURmVVOcLibWLORUBmgHC{ZYPzbY9v	NUjITYlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O\|U4Ojh\|PD;hQi=>
CD4+ T-cells	Ml;0SpVv[3Srb36gRZN{[Xl?	M4fUU\|UwOjBizszN	MlP2OFghcA>?		MV31dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[uKhWk:UzsP0xsA>	MnrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD4+ T-cells	M{OwV2Z2dmO2aX;uJGF{e2G7	MUW1M\|IxKM7:TR?=	M3;4OlQ5KGh?		MmnXbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN?	NVLPSGJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O\|U4Ojh\|PD;hQi=>
CD8+ T-cells	NWLCbIdMTnWwY4Tpc44hSXO\|YYm=	NXLv[IdYPS9{MDFOwG0>	NWTFPJBIPDhiaB?=		NUHENWNucW6qaXLpeJMhdWWvb4L5JHQu[2WubIO=	M3XkSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
CD3+ T-cells	Mlr5SpVv[3Srb36gRZN{[Xl?	NIXiTIo2KM7:TR?=	NFLVU3g1QCCq		MmK5doVlfWOnczDsc45oNXSncn2gcYVud3K7IHPlcIwheGinbn;0fZBm	M3rX[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
U937	MXzBdI9xfG:\|aYOgRZN{[Xl?	MXqxNEDPxE1?	NHTqW4c4OiCq		MV\pcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MEi2OUc,OjR4OEC4OlU9N2F-
HL-60	M{O0NmFxd3C2b4Ppd{BCe3OjeR?=	NYjNWXJIOTBizszN	MkLzO\|IhcA>?		NHSxcFdqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M4HId\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiwPFY2Lz5{NE[4NFg3PTxxYU6=
MCF7	NGfpcVdHfW6ldHnvckBCe3OjeR?=	NYPyNY5YPSEQvF2=	NWT4dnRSPDhiaNMg		NY\Wd45w\Gm\|cHzhfZMhe2WuZXP0bZZmKHSxeHnjbZR6KHSxd3Hy[EB{fXOyZX7k[YQhVUOILUegZ4VtdHN?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|M{O1NEc,OjR4M{OzOVA9N2F-
MCF7	MnHySpVv[3Srb36gRZN{[Xl?	M{HFN\|ExKM7:TR?=	NVrnZXU5OjRiaNMg		NUTIRpdpcW6mdXPld{B1cGViY3zlZZZi\2Vib3[gZ4F{eGG\|ZTC3JIFv\CCSQWLQxsA>	Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN\|UxRC:jPh?=
MCF7	NI\HdZJHfW6ldHnvckBCe3OjeR?=	MVyw5qCUOC53IN88UeKh	MV:3JIQ>		M3vPS4lvcGmkaYTzJJRp\SCpcn;3eIghVUOILUegeJVud3K\|cHjldoV{KGmwIIP1d5BmdnOrb36gZ5VtfHW{ZYRCpC=>	NF;UbJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MCF7	NWK0WJBjTnWwY4Tpc44hSXO\|YYm=	Ml:0NE42KM7:TdMg	MmfzNVQh\A>?		M4rzZ5Jm\HWlZYOgeIhmKHOrenWgc4YhVUOILUegZ49td26rZYOg[Y1j\WSmZXSgbY4he2:odDDh[4Fz	NF\uXlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MCF7	MXzGeY5kfGmxbjDBd5NigQ>?	Ml[yNE4xPeLCk{KwJO69VQ>?	NX:0cnhzOSCm		NYnL[VJEemWmdXPld{B1cGViY3zvcoFtKHO3co\peoFtKG:oIF3DSk04KGOnbHzzJIlvKG2xbn;sZZlmeiCldXz0eZJmew>?	NVrkPXJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|M{PTBpPkK0OlM{OzVyPD;hQi=>
T47D	Mo\QSpVv[3Srb36gRZN{[Xl?	NXzPSIJMOC53IN88US=>	M1zrTVQh\A>?		NYDXWmYxcW6qaXLpeJMhfHWvb4LzdIhmemViZn;ycYF1cW:w	NWfxcnViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|M{PTBpPkK0OlM{OzVyPD;hQi=>
MCF7	MnHBSpVv[3Srb36gRZN{[Xl?	M3XwPVAvPeLCk{GwJO69VQ>?	M4fPZlQ5KGkEoB?=		MXXpcohq[mm2czD0bIUh\2GyIHPsc5N2emViaX6geIhmKHexdX7kJIhm[WyrbnegZZN{[Xl?	NFm0dJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MCF7	NWn0e\|N1TnWwY4Tpc44hSXO\|YYm=	Mnz1NE8yOCEQvF2=	MnHPNlQhcA>?		MljPbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVFk>	M3PFdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOzN\|UxLz5{NE[zN\|M2ODxxYU6=
MDA-MB-231	MnLESpVv[3Srb36gRZN{[Xl?	NIniOGoxNjYkgKOxNEDPxE1?	MVyzOkBp		NGnMU4xqdmirYnn0d{B1cGVibXnndoF1cW:w	MlvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN\|UxRC:jPh?=
SKM1-S	NGnDPIxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXS0PEBpenN?		NX\jUXpjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT20yNVNiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhUUN3MDC9JFAvPSEQvF2u	M1n4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEm0PVM5Lz5{OEC5OFk{QDxxYU6=
SKM1-S	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXq0PEBpenN?		NVPVRlFmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT20yNVNiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGRCWElvc4ThbY5qdmdvYnHz[YQh\myxdzDjfZRwdWW2cnnjJI1mfGixZDygSWM2OCB;IECuOVEh\|ryPLh?=	MlK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyOUS5N\|goRjJ6MEm0PVM5RC:jPh?=
A427	NEX5em1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXq5OkBpenN?		NFr6b25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0Nlch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IHPyfZN1[WxidnnvcIV1KGG\|c3H5MEBKSzVyIE2gNE43OyEQvF2u	MmrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2M{SxOlMoRjF6NEO0NVY{RC:jPh?=
KYSE70	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnzmPVYhcHK\|		NUDjWZdxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLXXNGPzBiY3XscJMh[W[2ZYKgPVYhcHK\|IHL5JINzgXO2YXygeolwdGW2IHHzd4F6NCCLQ{WwJF0hOS53OTFOwG0v	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR\|NEG2N{c,OTh2M{SxOlM9N2F-
5637	MoSzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NETuW\|c6PiCqcoO=		NXHN[npuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjC1OlM4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDjdpl{fGGuII\pc4xmfCCjc4PhfUwhUUN3MDC9JFEvPzNizszNMi=>	M1jURVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEO0NVY{Lz5zOESzOFE3OzxxYU6=
HT-29	MlfoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Ml\ZPVYhcHK\|		NEm1SphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzMlgh\|ryPLh?=	NHjRSYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e4OFQ6Lz5{N{e4OFQ6RC:jPh?=
P388	M4rLZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NW\6Z4NOPDhiaILz		NGrSfI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIGCzPFgh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWg{txONg>?	NFzYUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e4OFQ6Lz5{N{e4OFQ6RC:jPh?=
MCF7	NUfBS5U5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYK5OkBpenN?		M3K2Z2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliY4L5d5RidCC4aX;s[ZQh[XO\|YYmsJGlEPTBiPTC2Mlc5KM7:TT6=	NILyb2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESzOFE3Oyd-MUi0N\|QyPjN:L3G+
U373-MAGI	NIi0[JNCdnSrdnnyZYwh[XO\|YYm=	NFS3WoszPSC2bzC0NFAhfU1?	M{DReVIhfG9iN{KgbJJ{		MkDzRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDnZYchdGW4ZXygZZQhOjVidH:gOFAxKHWPIHHmeIVzKDJidH:gO\|IhcHK\|IHL5JJFRS1JibXX0bI9l	MoCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI	MoPDRY51cX[rcnHsJIF{e2G7	MYSyOUB1dyB2MECgeW0>	MXyyJJRwKDd{IHjydy=>		NWjnbG8xSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBWPS2pYXegcIV3\WxiYYSgNlUhfG9iNECwJJVOKGGodHXyJFIhfG9iN{KgbJJ{KGK7IIHQR3IhdWW2aH;k	NF60bY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+
L1210	MXHDfZRwfG:6aXPpeJkh[XO\|YYm=				MkOzR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFEzOTBiY3XscJMh[XO\|ZYPz[YQh[XNiY3Xzd4F1cW:wIH;mJIdzd3e2aB?=	NGrOR4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi94OUCyOkc,PjlyMk[8M4E,
TC32	M2DEdZFJXFNiYYPzZZk>				NFe2fZJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	NUPnSWw6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	Mlr4dWhVWyCjc4PhfS=>				M1LUe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	NH\XOWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NUXBV254eUiWUzDhd5NigQ>?				MnPadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	MnX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	MnXtdWhVWyCjc4PhfS=>				M17Rc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	NGjq[4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	Mlm3dWhVWyCjc4PhfS=>				NGHQVWpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	M3XmelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MXrxTHRUKGG\|c3H5				M4LMd5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	NH;jWHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NVW5dZlKeUiWUzDhd5NigQ>?				NFW4fWNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NW\NWmFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M3u0NJFJXFNiYYPzZZk>				M1X3UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NX7tVm1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SKM1-S	NVnldFU{SXCxcITvd4l{KGG\|c3H5	NH\SWlkyKHWP			MnPYTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS12xMXMh[2WubIOgZZN{\XO\|ZXSgZZMh[2G\|cHHz[UA{KGOuZXH2ZYdmKGG2IEGgeW0h[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	M1XaUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEm0PVM5Lz5{OEC5OFk{QDxxYU6=
MCF7	M4fldmZ2dmO2aX;uJIF{e2G7	MX2xOUB2VQ>?	MXq3NkBpenN?		MULJcohq[mm2aX;uJI9nKFWKUl[xJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gcYV1cHmuYYTpc44h[XRiUlHSJIJmfGFiZYjvckBifCBzNTD1UUBi\nSncjC3NkBpenNiYomgcYV1cHmuYYTpc44he3CnY3nmbYMuWEOUIH3leIhw\A>?	NH22UXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C0PVU4Pyd-MkewOFk2Pzd:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control. c-PARP / p-H2AX / H2AX; PubMed: 28210112 Lung Cancer (Auckl) AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘	28210112
Immunofluorescence	HMGB1 ; PubMed: 29097772 Sci Rep U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕𢡄⟼෕䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemｾ᎒	29097772
Growth inhibition assay	Cell viability ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖	28210112

In vivo

Azacitidine inhibits polynucleotide synthesis in leukemic BDF₁ mice. ^[3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. ^[4]

Protocol

Cell Research:^[3]	- Collapse Cell lines: Leukemia L1210 cell Concentrations: 0.15 μg/mL Incubation Time: 3 days Method: 5 mL of L1210 cells (5 × 10³ cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: BDF1 mice bearing lymphoid leukemia L1210 Dosages: 3 mg/kg Administration: Daily i.p. injection (Only for Reference)

References

[4] Heby O, et al. Cancer Res. 1973, 33(1), 159-165.

- Collapse

Solubility (25°C)

In vitro	DMSO	48 mg/mL warmed (196.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Azacitidine (5-Azacytidine) SDF

Molecular Weight	244.2
Formula	C₈H₁₂N₄O₅
CAS No.	320-67-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	5-AzaC,Ladakamycin, AZA,5-Aza, CC-486
Smiles	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04891068	Recruiting	Drug: Azacitidine	Breast Cancer Female\|Breast Cancer Invasive	University of Illinois at Chicago	October 2021	Phase 2
NCT04722601	Not yet recruiting	Drug: Venetoclax\|Drug: Obinutuzumab\|Drug: CC-486	Follicular Lymphoma	University of Chicago	September 2021	Phase 1\|Phase 2
NCT05001828	Not yet recruiting	Drug: ADI-PEG 20	Acute Myeloid Leukemia Adult	Polaris Group	August 2021	Phase 1
NCT04912063	Suspended	Drug: Lemzoparlimab\|Drug: Azacitidine\|Drug: Venetoclax	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	AbbVie	June 25 2021	Phase 1
NCT04737343	Not yet recruiting	Drug: Leflunomide\|Drug: Azathioprine Tablets	ANCA Associated Vasculitis\|Maintenance Therapy	Chinese SLE Treatment And Research Group\|Shanghai Zhongshan Hospital\|Affiliated Hospital of Jilin University ChangchunChina\|Second Affiliated Hospital of Nanchang University\|The First Affiliated Hospital of Anhui Medical University\|Beijing Shijitan Hospital Capital Medical University\|The Affiliated Hospital of Inner Mongolia Medical University\|The First Affiliated Hospital of Kunming Medical College\|Sichuan Province People''s Hospital\|Second Affiliated Hospital School of Medicine Zhejiang University	May 1 2021	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?
Answer:
S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

Choose Your Country or Region

By Signaling Pathways

By product type

Azacitidine (5-Azacytidine)